Log in or Sign up for Free to view tailored content for your specialty!
Cardiometabolic Disorders News
Tirzepatide cuts risk for progression to type 2 diabetes for adults with prediabetes
Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line results from the SURMOUNT-1 3-year study.
Levels of some circulating proteins may inform care of comorbid obesity, heart failure
Twelve circulating proteins associated with obesity and heart failure may inform treatment for adults with both conditions, according to a study published in Obesity.
Log in or Sign up for Free to view tailored content for your specialty!
Medicare announces price cuts for 10 drugs in first round of drug price negotiations
The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.
Adults with type 2 diabetes improve HbA1c, medication use with pharmacist referral
Adults with type 2 diabetes who are referred to a clinical pharmacist are more likely to meet their HbA1c goal and receive appropriate medication management of comorbidities than people receiving usual care, according to a presenter.
Top-line data show significant weight loss with HU6 in patients with obesity-related HFpEF
HU6, a controlled metabolic accelerator, met the primary endpoint of weight reduction in patients with obesity-related heart failure with preserved ejection fraction, according to top-line results of the phase 2a HuMAIN trial.
Kidney, CV outcomes similar for SGLT2 inhibition vs. GLP-1s for diabetes
SGLT2 inhibitors were associated with similar renal and CV outcomes vs. GLP-1 receptor agonists for patients with diabetes, regardless of chronic kidney disease status, researchers reported.
SGLT2 inhibitors greatly underprescribed in patients who qualify for them
In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.
GLP-1 use tied to lower risk for hyperkalemia than DPP-IV therapy in type 2 diabetes
Adults with type 2 diabetes using a GLP-1 receptor agonist are less likely to develop hyperkalemia than those using a DPP-IV inhibitor, according to a study published in JAMA Internal Medicine.
Tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s
Adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists, according to observational data published in JAMA Network Open.
Adults maintain drops in body weight, HbA1c at 1 year after duodenal mucosal resurfacing
Adults with obesity and type 2 diabetes had reductions in body weight and HbA1c 1 year after undergoing an endoscopic procedure that resurfaces the duodenum lining, according to top-line results from a real-world registry study.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read